Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Conditions

Arthritis, Rheumatoid 1

Interventions

Methotrexate 10Adalimumab 6tocilizumab 5Rituximab 5olokizumab 4tofacitinib 3Etanercept 3golimumab 2RC-18 2Abatacept 2veltuzumab 1upadacitinib 1secukinumab 1sarilumab 1mavrilimumab 1baricitinib 1andecaliximab 1Tumor Necrosis Factor Inhibitors 1TACI receptor-IgG Fc fragment fusion protein 1Sulfasalazine 1Pharmaceutical Preparations 1Leflunomide 1Interleukin 1 Receptor Antagonist Protein 1Infliximab 1ISIS104838 1Hydroxychloroquine 1Folic Acid 1Double-Blind Method 1Chloroquine 1CT-P13 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Arthritis, Rheumatoid × mavrilimumab × Clear all
NCT01715896 2016-10-31

A Study of Mavrilimumab Versus Anti Tumor Necrosis Factor in Subjects With Rheumatoid Arthritis

MedImmune LLC

Phase 2 Completed
215 enrolled 37 charts

Arthritis, Rheumatoid

Data powered by HemOnc (CC BY 4.0) Colophon âš¡